Cargando…

(32)P in the treatment of myeloproliferative disorders

(32)P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years. It was first used in 1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias. With the introduction of agents such as hydroxycarbamide, interferon and anagrelide the rol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawless, Sarah, McMullin, Mary Frances, Cuthbert, Robert, Houston, Russell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Ulster Medical Society 2016
Materias:	Clinical Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920483/ https://www.ncbi.nlm.nih.gov/pubmed/27601760

Ejemplares similares

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
por: Greenfield, Graeme, et al.
Publicado: (2018)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

A Comparison of Inpatient and Outpatient-Based Chemotherapy Regimens for the Treatment of Acute Myeloid Leukaemia In The Elderly
por: Daly, A.B., et al.
Publicado: (2019)

Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
por: Duncombe, Andrew S., et al.
Publicado: (2020)

Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study
por: McMullin, Mary Frances, et al.
Publicado: (2016)

Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
por: McMullan, RR, et al.
Publicado: (2019)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Presidential address to the Ulster Medical Society on 3rd October 2019
por: McMullin, Mary Frances
Publicado: (2020)

Genetic Background of Congenital Erythrocytosis
por: McMullin, Mary Frances
Publicado: (2021)

Transcription and Qualitative Methods: Implications for Third Sector Research
por: McMullin, Caitlin
Publicado: (2021)

The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells
por: Clarke, Kathryn, et al.
Publicado: (2019)

Allogeneic Bone Marrow Transplant in Belfast – An outcome overview of the first 25 years
por: Cargo, Catherine A, et al.
Publicado: (2008)

Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia
por: Liberante, Fabio Giuseppe, et al.
Publicado: (2015)

Chronic Myeloid Leukaemia in The 21st Century
por: Frazer, Rachel, et al.
Publicado: (2007)

Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13,+15 double trisomy resulting in an adverse outcome
por: McGrattan, Peter, et al.
Publicado: (2007)

FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders
por: Ozdemirkiran, Fusun Gediz, et al.
Publicado: (2016)

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
por: Sobas, Marta, et al.
Publicado: (2022)

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
por: Weir, Philip, et al.
Publicado: (2023)

CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients
por: Weir, Philip, et al.
Publicado: (2022)

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
por: Fang, Zijian, et al.
Publicado: (2023)

Protein tyrosine phosphatase receptor type C (PTPRC or CD45)
por: Al Barashdi, Maryam Ahmed, et al.
Publicado: (2021)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
por: Salisbury, Richard A., et al.
Publicado: (2021)

Systemic Therapy In Acquired Haemophilia – A Single Institute Experience
por: Sarah, Lawless, et al.
Publicado: (2016)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Standardization Is Necessary in the Methods to Assess the Value of Electronic Prescribing Systems
por: McMullin, S. Troy
Publicado: (2005)

Newton on matter and activity
por: McMullin, Ernan
Publicado: (1994)

P989: DYNAMIC CHANGES IN THE HISTONE H3 LYSINE 27 TRIMETHYLATION EPIGENETIC LANDSCAPE FOLLOWING RUXOLITINIB ADMINISTRATION
por: Greenfield, G., et al.
Publicado: (2022)

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders
por: Palmblad, Jan, et al.
Publicado: (2008)

The 8p12 myeloproliferative syndrome
por: Sarahx, O. John-Olabode, et al.
Publicado: (2014)

Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
por: Greenfield, Graeme, et al.
Publicado: (2019)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Complicated ventricular arrhythmia and hematologic myeloproliferative disorder in RIT1‐associated Noonan syndrome: Expanding the phenotype and review of the literature
por: Aly, Safwat A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n2grfl992j433v6tvttqn58k2q